BACKGROUND: Morphological and functional changes to sinusoidal endothelial cells mediated by soluble factors released from activated Kupffer cells, including cytokines, are considered pivotal events in ischemia/reperfusion injury (IRI) to liver grafts. Vascular endothelial growth factor (VEGF) is an endothelial cell-specific cytokine with potent pro-inflammatory and mitogenic effects. We investigated the possible role of VEGF in IRI to liver grafts using a syngeneic rat orthotopic liver transplantation model. METHODS: Transplantation was performed in Lewis rats using livers preserved for various periods of time (24-48 hr) in University of Wisconsin solution at 4 degrees C. Systemic VEGF levels were measured by enzyme-linked immunosorbent assay (ELISA). Intrahepatic VEGF expression was analyzed by Northern blotting and in situ hybridization. The effects of anti-VEGF neutralizing antibody treatment on the extent of IRI were assessed by measuring liver function tests, lipid peroxidation, and metalloproteinase activity. RESULTS/ CONCLUSION: VEGF is expressed and released in a biphasic pattern during the early postoperative period after liver transplantation. Anti-VEGF antibody treatment, administered during reperfusion, decreased the degree of damage, suggesting that VEGF may have a role in IRI to liver grafts.
BACKGROUND: Morphological and functional changes to sinusoidal endothelial cells mediated by soluble factors released from activated Kupffer cells, including cytokines, are considered pivotal events in ischemia/reperfusion injury (IRI) to liver grafts. Vascular endothelial growth factor (VEGF) is an endothelial cell-specific cytokine with potent pro-inflammatory and mitogenic effects. We investigated the possible role of VEGF in IRI to liver grafts using a syngeneic rat orthotopic liver transplantation model. METHODS: Transplantation was performed in Lewis rats using livers preserved for various periods of time (24-48 hr) in University of Wisconsin solution at 4 degrees C. Systemic VEGF levels were measured by enzyme-linked immunosorbent assay (ELISA). Intrahepatic VEGF expression was analyzed by Northern blotting and in situ hybridization. The effects of anti-VEGF neutralizing antibody treatment on the extent of IRI were assessed by measuring liver function tests, lipid peroxidation, and metalloproteinase activity. RESULTS/ CONCLUSION:VEGF is expressed and released in a biphasic pattern during the early postoperative period after liver transplantation. Anti-VEGF antibody treatment, administered during reperfusion, decreased the degree of damage, suggesting that VEGF may have a role in IRI to liver grafts.
Authors: Sei-ichiro Tsuchihashi; Bibo Ke; Fady Kaldas; Evelyn Flynn; Ronald W Busuttil; David M Briscoe; Jerzy W Kupiec-Weglinski Journal: Am J Pathol Date: 2006-02 Impact factor: 4.307
Authors: Alessandra Milesi-Hallé; Sandra McCullough; Jack A Hinson; Richard C Kurten; Laura W Lamps; Aliza Brown; Laura P James Journal: Basic Clin Pharmacol Toxicol Date: 2011-11-09 Impact factor: 4.080
Authors: Bibo Ke; Xiu-Da Shen; Feng Gao; Seiichiro Tsuchihashi; Douglas G Farmer; David Briscoe; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Transplantation Date: 2005-05-15 Impact factor: 4.939
Authors: Ashish Francis; Shawna R Kleban; Linda L Stephenson; Patrick S Murphy; Peter R Letourneau; Xin-Hua Fang; Wei Z Wang; Richard C Baynosa Journal: Plast Reconstr Surg Glob Open Date: 2017-09-25